FDA Chief Counsel Troy Brings WLF Experience To Post
This article was originally published in The Tan Sheet
Executive Summary
FDA Chief Counsel-designate Daniel Troy is one of the attorneys who successfully challenged the agency's approach to off-label promotion in the Washington Legal Foundation v. Henney suit.
You may also be interested in...
Allen, Azar & Troy: FDA Legal Partners Streamline Enforcement Activity
HHS' decision to elevate FDA warning letter oversight from the Office of Regulatory Affairs to the Office of the Chief Counsel signals an attempt to keep a tighter rein on the agency in the absence of a commissioner
FDA "National Security" Mission: Counterfeiting And Bioterrorism?
FDA should heighten its focus on product security to ensure counterfeiting does not take place, not only for consumer safety, but to cut off a source of income for terrorists, asserted House Energy & Commerce Committee Senior Counsel Alan Slobodin.
WLF Ruling Could Invalidate DSHEA Restrictions, Attorney Says
Four of the five Dietary Supplement Health & Education Act restrictions on dissemination of third-party literature could constitute First Amendment violations under a federal judge's recent ruling on the distribution of off-label drug use studies, according to a D.C. attorney who represents dietary supplement makers.